IFRX (inflarx.de) רווח נקי

InflaRx N.V. (IFRX) dominates emergency medicine thanks to its unique drug Gohibic, which provides significant pricing power. The company's personnel policy relies on recruiting leading German immunologists. The company's net operating profit on this chart demonstrates financial stability, where 0.00 is the current level of the indicator. Technological development is based on the implementation of laboratory robotics to automate the search for new therapeutic molecules.

This indicator tracks daily net income, allowing for the determination of long-term trend sustainability and the probability of capital drawdowns without relying on trading volumes. By analyzing the company's surplus income, an investor assesses the real profitability of the business, where even the standard costs of InflaRx N.V. (IFRX) for regulated environmental laboratory cleaning are reflected in the final profit dynamics.